Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marlo Whitehead

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2008
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21Chang-Qi Zhu, Gilda da Cunha Santos, Keyue Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2007
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20Andrew M Arnold, Lesley Seymour, Michael Smylie, et al.
The New England Journal of Medicine|July 15, 2005
Erlotinib in lung cancer - molecular and clinical predictors of outcomeMing-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2008
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21Chang-Qi Zhu, Gilda da Cunha Santos, Keyue Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2007
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20Andrew M Arnold, Lesley Seymour, Michael Smylie, et al.
The New England Journal of Medicine|July 15, 2005
Erlotinib in lung cancer - molecular and clinical predictors of outcomeMing-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, et al.
Pageof 8